Additional file 1: of Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

Keilholz, Ulrich; Mehnert, Janice; Bauer, Sebastian; Bourgeois, Hugues; Patel, Manish; Gravenor, Donald; Nemunaitis, John; Taylor, Matthew; Wyrwicz, Lucjan; Lee, Keun-Wook; Kasturi, Vijay; Chin, Kevin; Heydebreck, Anja; Gulley, James

doi:10.6084/m9.figshare.7598207.v1

40425_2018_459_MOESM1_ESM.pdf (31.92 kB)

Additional file 1: of Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

journal contribution

posted on 2019-01-16, 05:00 authored by Ulrich Keilholz, Janice Mehnert, Sebastian Bauer, Hugues Bourgeois, Manish Patel, Donald Gravenor, John Nemunaitis, Matthew Taylor, Lucjan Wyrwicz, Keun-Wook Lee, Vijay Kasturi, Kevin Chin, Anja Heydebreck, James Gulley

Table S1. ORR according to tumor site subgroups. (PDF 31âkb)

Funding

Merck KGaA, Darmstadt, Germany

History

Usage metrics

Keywords

PD-L1 Avelumab Immune checkpoint inhibitor Ocular melanoma Cutaneous melanoma

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1: of Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

Funding

Merck KGaA, Darmstadt, Germany

History

Usage metrics

Categories

Keywords

Licence

Exports